1 Neurobiologisk Forskning, Department of Molecular Medicine, Det Sundhedsvidenskabelige Fakultet, SDU2 Neurology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU3 Department of Oncology, Institute of Regional Health Research, Det Sundhedsvidenskabelige Fakultet, SDU4 Department of Oncology, Lillebaelt Hospital, Vejle, Denmark5 Department of Oncology, Institute of Regional Health Research, Det Sundhedsvidenskabelige Fakultet, SDU6 Neurobiologisk Forskning, Department of Molecular Medicine, Det Sundhedsvidenskabelige Fakultet, SDU7 Neurology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
Many questions with few answers
Oxaliplatin is a chemotherapeutic agent effective against advanced colorectal cancer. Unlike with other platinum-based agents, the main side effect of oxaliplatin is polyneuropathy. Oxaliplatin-induced polyneuropathy (OIPN) has a unique profile, which can be divided into acute and chronic neurotoxicity. Early identification of the neurotoxicity and alterations in dose or schedule for the medication could prevent the development of chronic symptoms, which, once established, may take many months or years to resolve or even persist throughout life with a substantial effect on quality of life. There is no doubt that the use of pharmacogenomic methods to identify genetic bases of interindividual differences in drug response has led to what is called tailoring treatment. Yet there are some challenges regarding the application of these differences. Many efforts have been made to prevent or treat OIPN. Better understanding of the mechanisms underlying the acute and chronic forms of OIPN will be a key component of future advances in the prevention and treatment of OIPN. The aim of this review is to highlight the clinical presentation, assessment, and management of OIPN, as well as the underlying pathophysiologic and pharmacogenomic background.
Journal review article
Clinical Colorectal Cancer, 2014, Vol 13, Issue 2, p. 73-80